title: Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study).
abstract: We studied the penetration of raltegravir and HIV shedding in the genital tract among 14 HIV-1-infected women receiving a raltegravir-containing regimen who had <40 copies/ml blood plasma (BP) HIV RNA. None of the cervicovaginal fluid (CVF) samples showed detectable HIV RNA. Median raltegravir concentrations were 235 ng/ml in BP and 93 ng/ml in CVF, with a CVF/BP ratio of approximately 2.3. This good penetration of raltegravir may contribute to the control of viral replication in the female genital tract.
authors: Department of Infectious Diseases, Pitié-Salpêtrière Hospital, Boulevard de l'Hôpital, Paris 75013, France. drcyrilclavel@yahoo.fr
authors: Cyril
authors: C
authors: Clavel
authors: Gilles
authors: G
authors: Peytavin
authors: Roland
authors: R
authors: Tubiana
authors: Cathia
authors: C
authors: Soulié
authors: Catherine
authors: C
authors: Crenn-Hebert
authors: Isabelle
authors: I
authors: Heard
authors: François
authors: F
authors: Bissuel
authors: Houria
authors: H
authors: Ichou
authors: Claudia
authors: C
authors: Ferreira
authors: Christine
authors: C
authors: Katlama
authors: Anne-Geneviève
authors: AG
authors: Marcelin
authors: Laurent
authors: L
authors: Mandelbrot
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000328:Adult; D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D002584:Cervix Uteri / Q000378:metabolism*; D005260:Female; D015497:HIV-1; D006801:Humans; D008875:Middle Aged; D011760:Pyrrolidinones / Q000493:pharmacokinetics*; D000068898:Raltegravir Potassium; D014621:Vagina / Q000378:metabolism*
chemical_list: D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium